5/30
12:14 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Evercore ISI from $15.00 to $7.00. They now have an "in-line" rating on the stock.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Evercore ISI from $15.00 to $7.00. They now have an "in-line" rating on the stock.
5/28
02:37 pm
edit
Azzur Cleanrooms on Demand™ Grand Opening in Devens, MA Brings Together Local, State and Life Sciences Leaders [Yahoo! Finance]
Low
Report
Azzur Cleanrooms on Demand™ Grand Opening in Devens, MA Brings Together Local, State and Life Sciences Leaders [Yahoo! Finance]
5/14
10:06 am
edit
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June [Yahoo! Finance]
Low
Report
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June [Yahoo! Finance]
5/14
10:00 am
edit
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
Medium
Report
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
5/12
08:26 am
edit
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
Medium
Report
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
5/10
06:19 am
edit
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]
Medium
Report
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]
5/10
06:00 am
edit
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Medium
Report
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
5/10
12:31 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
5/9
03:48 pm
edit
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/9
03:41 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Citigroup Inc. from $16.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Citigroup Inc. from $16.00 to $15.00. They now have a "buy" rating on the stock.
5/9
02:42 pm
edit
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down [Yahoo! Finance]
Low
Report
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down [Yahoo! Finance]
5/9
01:18 pm
edit
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5? [Yahoo! Finance]
Low
Report
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5? [Yahoo! Finance]
5/9
11:09 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Barclays PLC from $11.00 to $9.00. They now have an "equal weight" rating on the stock.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Barclays PLC from $11.00 to $9.00. They now have an "equal weight" rating on the stock.
5/9
07:03 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating. They now have a $7.00 price target on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating. They now have a $7.00 price target on the stock.
5/9
06:44 am
edit
Editas Medicine First Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
Medium
Report
Editas Medicine First Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
5/8
07:08 am
edit
Editas Medicine Announces First Quarter 2024 Results and Business Updates [Yahoo! Finance]
Medium
Report
Editas Medicine Announces First Quarter 2024 Results and Business Updates [Yahoo! Finance]
5/8
07:00 am
edit
Editas Medicine Announces First Quarter 2024 Results and Business Updates
High
Report
Editas Medicine Announces First Quarter 2024 Results and Business Updates
5/6
10:40 am
edit
Experimental gene therapy restores some vision in patients with inherited blindness [CNN]
Low
Report
Experimental gene therapy restores some vision in patients with inherited blindness [CNN]
5/6
09:12 am
edit
Experimental gene therapy restores some vision in patients with inherited blindness [CNN]
Low
Report
Experimental gene therapy restores some vision in patients with inherited blindness [CNN]
5/5
09:28 am
edit
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71% [Yahoo! Finance]
Low
Report
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71% [Yahoo! Finance]
5/2
07:13 am
edit
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events [Yahoo! Finance]
Low
Report
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events [Yahoo! Finance]
5/2
07:00 am
edit
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
Low
Report
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
5/1
08:19 am
edit
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration [Yahoo! Finance]
Medium
Report
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration [Yahoo! Finance]
5/1
08:00 am
edit
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Medium
Report
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
4/22
04:46 pm
edit
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]
Medium
Report
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]